Skip to main content
. 2021 Dec 2;5(23):4992–5001. doi: 10.1182/bloodadvances.2021004735

Figure 3.

Figure 3.

EFS by receipt of gemtuzumab in Black vs non-Black patients with CBF AML. (A) Non-Black patients. (B) Black patients.